Trump was hosting a news conference to announce a new agreement with drug manufacturers Novo Nordisk and Eli Lilly to broaden access to GLP-1 medications, including Ozempic and Wegovy.
The oral version of the medications is expected to be offered for as low as $149 per month, once approved by the U.S. Food and Drug Administration.
The injectable GLP-1 medications will drop to $245 per month for patients on Medicare or Medicaid who utilize them to treat medical conditions such as diabetes that have already been approved by the FDA.